Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.

ABSTRACT:

Importance

Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.

Objective

To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS.

Design, setting, and participants

This multicenter, rater-blinded, noninferiority randomized clinical trial was conducted between July 1, 2020, and March 20, 2023, at 14 Dutch centers. Data analysis was performed between July 2023 and January 2024. Key inclusion criteria were relapse-onset MS, aged 18 years or older, without relapses, and without substantia

SUBMITTER: Coerver EME 

PROVIDER: S-EPMC11811793 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature